The round, anchored by Aaron Fleck & Associates, was raised at over $50m post-money valuation.
The company intends to use the funds to advance a product portfolio of science-driven innovations, further strengthening the promise of sexual empowerment for all women.
Led by Chief Executive Officer Nial DeMena, and Chief Operating Officer Carolyn Vella, Vella Bioscience provides Pleasure Serum, a clinically demonstrated pre-play topical serum that promotes increased arousal and lubrication, and intense, orgasms.
Co-founded by Dr. Harin Padma-Nathan, the lead Principal Investigator for Viagra
® and Cialis
®, the company’s proprietary nano-encapsulated CBD technology delivers CBD beyond the skin to relax vaginal and clitoral smooth muscle to encourage arousal and orgasm.
Share this article
Share this article
LOS ANGELES, May 3, 2021 /PRNewswire/ Vella Bioscience, Inc. today announced its formation as a femtech company driven to put science in service of every woman s sexual empowerment. The company launches with its breakthrough flagship product – Vella Women s Pleasure Serum, a first-of-its-kind pre-play topical serum to promote more frequent, intense, and satisfying orgasms for every cis woman – whether solo or with a partner.
Founded by a team of medical researchers, scientists and beauty industry experts, Vella leads the intersection of proprietary science and luxury beauty for sexual wellness. For the past century, men have had powerful medical support for their sexual wellness, yet support for female sexual wellness has been viewed as too complex. Dr. Harin Padma-Nathan, the lead Principal Investigator for Viagra® and Cialis®, alongside esteemed chemist and Chief Product Officer Dr. Michael Frid, saw the opportunity to simplify f